KYNB

7.12

3.39% -0.25

Dopo l'orario di chiusura: 7.12

Kyntra Bio Inc (KYNB)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$7.37

Aprire:

$7.35

Volume 24 ore:

8,914

Relative Volume:

0.29

Capitalizzazione di mercato:

$28.81M

Reddito:

$6.44M

Utile/perdita netta:

$-58.21M

Rapporto P/E:

0.2277

EPS:

31.2684

Flusso di cassa netto:

$-4.86M

1 W Prestazione:

-2.47%

1M Prestazione:

+2.15%

6M Prestazione:

+0.00%

1 anno Prestazione:

+0.00%

Intervallo 1D:

$7.09

$7.36

Intervallo di 1 settimana:

$7.02

$7.455

Portata 52W:

$6.32

$9.58

Kyntra Bio Inc Stock (KYNB) Company Profile

Nome

Kyntra Bio Inc

Settore

Healthcare (1112)

Industria

Biotechnology (621)

Telefono

415-978-1200

Indirizzo

350 BAY STREET, SAN FRANCISCO

Dipendente

Cinguettio

Prossima data di guadagno

2026-03-16

Ultimi documenti SEC

KYNB's Discussions on Twitter

Compare KYNB vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KYNB Kyntra Bio Inc	7.12	29.83M	6.44M	-58.21M	-4.86M	31.27
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-08	Downgrade	BofA Securities	Neutral → Underperform
2023-06-26	Downgrade	BofA Securities	Buy → Neutral
2023-06-26	Downgrade	Raymond James	Outperform → Mkt Perform
2023-06-26	Downgrade	Stifel	Buy → Hold
2023-06-26	Downgrade	William Blair	Outperform → Mkt Perform
2023-06-02	Aggiornamento	Stifel	Hold → Buy
2023-01-31	Aggiornamento	William Blair	Mkt Perform → Outperform
2023-01-26	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-01-05	Aggiornamento	BofA Securities	Neutral → Buy
2021-09-22	Downgrade	Goldman	Neutral → Sell
2021-08-20	Aggiornamento	Raymond James	Underperform → Mkt Perform
2021-07-16	Downgrade	BofA Securities	Buy → Neutral
2021-07-16	Downgrade	Stifel	Buy → Hold
2021-04-07	Downgrade	H.C. Wainwright	Buy → Neutral
2021-04-07	Downgrade	Mizuho	Buy → Neutral
2021-03-31	Aggiornamento	BofA Securities	Neutral → Buy
2021-03-02	Downgrade	Jefferies	Buy → Hold
2021-02-01	Iniziato	H.C. Wainwright	Buy
2020-10-26	Iniziato	Raymond James	Underperform
2020-07-10	Ripresa	Stifel	Buy

Mostra tutto

Kyntra Bio Inc Borsa (KYNB) Ultime notizie

Apr 14, 2026

Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Apr 14, 2026

Apr 12, 2026

What date does Kyntra Bio Inc's (KYNB) report EarningsEarnings Calendar & Announcement - Zacks Investment Research

Apr 12, 2026

Apr 10, 2026

Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart

Apr 10, 2026

Apr 09, 2026

Kyntra Bio Faces Nasdaq Compliance Challenge After Revenue Shift - TipRanks

Apr 09, 2026

Kyntra Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets

Apr 09, 2026

Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan

Apr 09, 2026

KYNB Stock Price, Quote & Chart | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill

Apr 09, 2026

Apr 08, 2026

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget

Apr 08, 2026

Apr 04, 2026

KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill

Mar 25, 2026

Mar 22, 2026

If You Invested $1,000 in Fibrogen Inc (FGEN) - Stock Titan

Mar 22, 2026

Mar 17, 2026

Advancing Pipeline and 2026 Clinical Catalysts Underpin Buy Rating on Kyntra Bio - tipranks.com

Mar 17, 2026

Kyntra Bio, Inc. 2023 Annual Report: Business Overview, Risk Factors, and Financial Highlights - Minichart

Mar 17, 2026